For the first time, a major trigger in inflammatory bowel disease (IBD) and related conditions has been identified, and existing drugs can stamp it out, in what scientists call a "massive step" in ...

Early and aggressive immunosuppressive therapy with tumor necrosis factor (TNF) inhibitors significantly outperformed conventional therapy for patients with newly diagnosed Crohn's disease and should ...

ISM5411 is an oral, PHD 1/2-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. ISM5411 is Insilico Medicine’s fifth AI-driven drug ...

HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns.

The discovery that a toxin made by bacteria found in dirty water might help trigger ulcerative colitis could lead to new ...